HDFC Pharma and Healthcare Fund Regular Growth
Medium
Risk
Equity
Other
+
0.00
%
0.00
%
3Y annualised
+
-0.04
%
-0.04
%
1D
1M
6M
1Y
3Y
All
Fund size
732
NAV:
Mar 7, 2024
12.253
Sector
Tech
Type
Equity
Launched
Oct 2023
Min Investment
100
Expense Ratio
2
Risk
Medium
Portfolio allocation
Top 10 Holdings
% Value
Sun Pharmaceuticals Industries Ltd
13.86
%
Cipla Ltd
7.95
%
Lupin Ltd
5.7
%
Ajanta Pharma Ltd
5.19
%
Dr Reddy's Laboratories Ltd
4.50
%
Torrent Pharmaceuticals Ltd
4.36
%
Krishna Institute of Medical Sciences Ltd
4.31
%
Max Healthcare Institute Ltd Ordinary Shares
3.65
%
Metropolis Healthcare Ltd
3.21
%
Thyrocare Technologies Ltd
3.05
%
Expense ratio, exit load and tax
Expense Ratio:
2
%
Inclusive of GST
Exit load
Exit load of 1.0% if redeemed within 30.0 Days, 0.0 % if redeemed after 30.0 Days.
Tax implication
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
Fund house & investment objective
HDFC Pharma and Healthcare Fund Regular Growth
More details
Investment objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Scheme Information Document
Mutual Fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not an indicator of future returns.
Calculate returns
One-time
Monthly SIP
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
* Returns are calculated as per lifetime average per annum returns of the fund.
Calculate returns
Monthly SIP
One-time
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
![iphone_13_animation_vance](https://cdn.prod.website-files.com/6481d90c7b1a530e99e0e827/64b428024ae97984b4d6b55c_iPhone%2013%20Pro.webp)